JULY 2024LIFE SCIENCES REVIEW6The gene therapy arena has achieved significant milestones with the approval of groundbreaking CRISPR-based treatments for sickle cell disease, heralding a new chapter in the management of genetic disorders. These developments not only highlight the strides made in genome editing but pave the way for more precise and effective treatments for a broad range of diseases. Artificial intelligence (AI) is increasingly becoming a cornerstone in this progress, enhancing the precision of research, development and the customisation of medical treatments. Through the power of AI, the industry is moving toward treatments tailored to the unique genetic makeup of individuals, promising more targeted and effective approaches, especially for those battling rare diseases.Simultaneously, the scope of CAR-T cell therapies is broadening, extending its potential from treating hematological malignancies to tackling solid tumors and other complex health challenges. Despite encountering obstacles such as toxicity and variability in tumor targets, innovative solutions are being explored to circumvent these issues. Strategies like the development of in vivo induced CAR-T cells and the exploration of novel T cell therapies are at the forefront of these efforts, aiming to unlock new possibilities in treatment. Driven by these trends, the global cell and gene therapy market size is estimated to reach $24.67 billion by 2029, growing at a CAGR of 28 percent.This edition of Life Sciences Review examines the latest developments in the cell and gene therapy market across the European region. It features a thought leadership article by Dr. Linda Randall, AVP, Biologics Development, Manufacturing & Control, Pharmaron, outlining their plug-and-play viral vector manufacturing platforms to meet customised cell and gene therapy needs. This edition also brings to you the story of the top cell and gene therapy companies in Europe in 2024 and the top cell and gene therapy companies in the UK in 2024. We hope you find the right partner to meet your organisation's needs.Let us know your thoughts!EDITORIALGenetic Disorders Meet Genome Editing: A New Era of TreatmentCopyright © 2024 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasGilbert HooverAncel CastelinoDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsJuly - 10 - 2024, Vol 05, Issue - 08 ( ISSN 2831-8331) Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com VisualizersRonald DonovanVictor Cruz Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com
< Page 5 | Page 7 >